|Videos|March 22, 2017

How Does the Model of Prenatal Care Centering Work?

Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses how the model of prenatal care centering works.

Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses how the model of prenatal care centering works.

Interview Transcript (slightly modified for readability)

“The model of prenatal care centering is a model that has been implemented for more than 20 years. The model works this way: You have a group of 12 pregnant women with whoever they want, a significant other, present during the visits of all prenatal care. Part of the visit has an individual, private conversation with your provider and then instead of having a class, we have a conversation. We have topics that we cover in those conversations, like nutrition, exercise, when [to] come to the hospital, [and] signs of things that are abnormal.

So, in those conversations, people disclose what they want to; you’re not asking people specific questions and are forcing anybody to disclose anything. [Also], we do have groups of women exclusively with diagnoses of Zika, and in those groups, we discuss, in addition to things about pregnancy, the issues of Zika. We also have groups of women with diabetes or women with different other diagnoses, so the issues of confidentiality are not specific because these are just conversations that are part of a group, where people actually learn from each other; we learn from the best practices. It’s fascinating if you are a part of a group you can learn from women with diabetes and they will tell you, some of them will say, ‘Well, orange juice is better than grape juice when I have hypoglycemia,’ and as a physician, I did not know. So, I am also learning with them as well.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.